Advertisement

Topics

Cost Effectiveness of Repatha Weighed Using Various Clinical Scenarios

10:05 EDT 24 Aug 2017 | PharmPro

New economic analysis based on Repatha (evolocumab) outcomes data published in JAMA Cardiology. Repatha used in patients at high-risk for cardiovascular events is cost-effective at net prices at or below $9,669, study says.
Contributed Author: 
Amgen

Original Article: Cost Effectiveness of Repatha Weighed Using Various Clinical Scenarios

NEXT ARTICLE

More From BioPortfolio on "Cost Effectiveness of Repatha Weighed Using Various Clinical Scenarios"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...